iSAM Funds UK Ltd Takes Position in Cencora, Inc. $COR

iSAM Funds UK Ltd bought a new position in Cencora, Inc. (NYSE:COR) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 3,404 shares of the company’s stock, valued at approximately $1,021,000.

Other hedge funds have also added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC grew its stake in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares during the last quarter. Vermillion & White Wealth Management Group LLC boosted its holdings in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares during the period. Twin Peaks Wealth Advisors LLC bought a new position in Cencora during the 2nd quarter worth approximately $52,000. Caitong International Asset Management Co. Ltd purchased a new position in Cencora in the 2nd quarter worth approximately $61,000. Finally, ANTIPODES PARTNERS Ltd purchased a new position in Cencora in the 2nd quarter worth approximately $61,000. 97.52% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the sale, the chief executive officer directly owned 65,746 shares of the company’s stock, valued at $24,105,113.44. This represents a 7.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 46,640 shares of company stock worth $14,099,338. Company insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Wells Fargo & Company raised their target price on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Evercore ISI set a $400.00 price target on shares of Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Robert W. Baird boosted their price objective on shares of Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Barclays began coverage on shares of Cencora in a report on Monday. They set an “overweight” rating and a $400.00 target price for the company. Finally, JPMorgan Chase & Co. raised their target price on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and an average price target of $373.50.

Cencora Stock Performance

Cencora stock opened at $337.32 on Wednesday. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $377.54. The stock’s 50 day simple moving average is $341.14 and its two-hundred day simple moving average is $310.38. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The stock has a market cap of $65.44 billion, a price-to-earnings ratio of 42.43, a PEG ratio of 1.60 and a beta of 0.63.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a dividend of $0.60 per share. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s payout ratio is 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.